Literature DB >> 14604290

Intensified conditioning regimen has only limited value for patients with progressive multiple myeloma.

Naoki Takezako, Akiyoshi Miwa, Akira Tanimura, Chiho Inokuchi, Tateki Shikai, Noboru Yamagata, Atsushi Togawa.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14604290     DOI： 10.1007/bf02983808

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Authors:  B Barlogie; S Jagannath; K R Desikan; S Mattox; D Vesole; D Siegel; G Tricot; N Munshi; A Fassas; S Singhal; J Mehta; E Anaissie; D Dhodapkar; S Naucke; J Cromer; J Sawyer; J Epstein; D Spoon; D Ayers; B Cheson; J Crowley
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

2.  High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.

Authors:  A Badros; B Barlogie; C Morris; R Desikan; S R Martin; N Munshi; M Zangari; J Mehta; A Toor; M Cottler-Fox; A Fassas; E Anaissie; S Schichman; G Tricot; E Aniassie
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

3.  Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma.

Authors:  R Abraham; C Chen; R Tsang; D Simpson; C Murray; M Davidson; J Meharchand; D M Sutton; R M Crump; A Keating; A K Stewart
Journal:  Bone Marrow Transplant       Date:  1999-12       Impact factor: 5.483

4.  Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.

Authors:  K R Desikan; G Tricot; M Dhodapkar; A Fassas; D Siegel; D H Vesole; S Jagannath; S Singhal; J Mehta; D Spoon; E Anaissie; B Barlogie; N Munshi
Journal:  Bone Marrow Transplant       Date:  2000-03       Impact factor: 5.483

5.  Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.

Authors:  J J Lahuerta; J Martinez-Lopez; C Grande; J Bladé; J de la Serna; A Alegre; J García-Laraña; D Caballero; A Sureda; J de la Rubia; A M Alvarez; J Marín; A Escudero; E Conde; K Perez-Equiza; J C García Ruiz; J M Moraleda; A León; J Bargay; R Cabrera; M T Hernandez-García; J Diaz-Mediavilla; J S Miguel
Journal:  Br J Haematol       Date:  2000-04       Impact factor: 6.998

6.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.

Authors:  H M Lokhorst; A Schattenberg; J J Cornelissen; L L Thomas; L F Verdonck
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

7.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

8.  Graft-versus-myeloma effect: proof of principle.

Authors:  G Tricot; D H Vesole; S Jagannath; J Hilton; N Munshi; B Barlogie
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.